Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma
Martin-Algarra, S., Haanen, J.B., Horak, C., Bhatia, S., Ribas, A., Hwu, W-J., Slingluff,, C.L., Sharfman, W.H., Callahan, M., Hodi, F.S., Wolchok, J.D., Luke, J., Young, T.C., Qureshi, A., Urba, W.J.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw379.20
Date:
October, 2016
File:
PDF, 40 KB
english, 2016